Article
Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation.
International journal of cancer - 15 Mar 2015
Groenendijk Floris H, Mellema Wouter W, van der Burg Eline, Schut Eva, Hauptmann Michael, Horlings Hugo M, Willems Stefan M, van den Heuvel Michel M, Jonkers Jos, Smit Egbert F, Bernards René
Abstract excerpt
The multikinase inhibitor sorafenib is under clinical investigation for the treatment of many solid tumors, but in most cases, the molecular target responsible for the clinical effect is unknown. Furthermore, enhancing the effectiveness of sorafenib using combination strategies is a major clinical challenge. Here, we identify sorafenib as an activator of AMP-activated protein kinase (AMPK), in a manner that...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.